Sector News

Bristol Myers’ Caforio stepping down as CEO in November

April 29, 2023
Life sciences

After the transition is complete, Caforio will continue as chair of Bristol Myers’ board of directors, although it is not typical for U.S-based drugmakers to permanently split the CEO and board chair roles. The company said his tenure as chair will be “for a transition period to be determined by the board.”

Taking Boerner’s place as chief commercial officer will be Adam Lenkowsky, currently Bristol Myers’ head of major markets. That transition is effective immediately with Boerner’s elevation to COO.

A medical doctor, Caforio assumed the CEO’s role from Lamberto Andreotti in 2015 after having worked in numerous roles across the company, including as chief commercial officer and COO.

His tenure as Bristol Myers chief was defined by the company’s development of the blood thinner Eliquis and the cancer immunotherapy Opdivo into blockbuster medicines, as well as a string of big-ticket acquisitions, most notably a $74 billion acquisition of Celgene. That deal brought in the fast-selling blood cancer treatment Revlimid, making Bristol Myers one of the largest oncology companies, as well as the cancer cell therapies Abecma and Breyanzi, which now figure more prominently in its plans.

Yet Bristol Myers also misstepped under Caforio, choosing a clinical development plan for Opdivo that backfired and allowed rival Merck & Co. to take a leading position in the market for cancer immunotherapies. A big bet on an experimental immunotherapy developed by biotechnology company Nektar Therapeutics also didn’t pan out. READ MORE

By Jonathan Gardner


comments closed

Related News

June 3, 2023

Sanofi’s frexalimab shows early potential in in Phase II multiple sclerosis trial

Life sciences

In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.

June 3, 2023

Lonza to acquire Synaffix to strengthen ADC development

Life sciences

Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).

June 3, 2023

BD taps Novartis, GSK alum Laura Boros to lead drug delivery device business

Life sciences

In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.

How can we help you?

We're easy to reach